These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3610330)

  • 1. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.
    Malerczyk V; Maass L; Verho M; Hajdú P; Klesel N; Rangoonwala R
    Infection; 1987; 15(3):211-4. PubMed ID: 3610330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.
    Maass L; Malerczyk V; Verho M; Hajdú P; Seeger K; Klesel N
    Infection; 1987; 15(3):202-6. PubMed ID: 3610328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers.
    Maass L; Malerczyk V; Verho M
    Infection; 1987; 15(3):207-10. PubMed ID: 3610329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.
    Badian M; Malerczyk V; Collins JD; Dixon GT; Verho M; Eckert HG
    Chemotherapy; 1988; 34(5):367-73. PubMed ID: 3180904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers.
    Nakayama I; Akieda Y; Yamaji E; Nitta Y; Ohishi M; Katagiri K; Imamura N; Takase K
    J Clin Pharmacol; 1992 Mar; 32(3):256-66. PubMed ID: 1564130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
    Meyer BH; Muller FO; Luus HG; Drees B; Röthig HJ; Badian M; Eckert HG
    J Antimicrob Chemother; 1992 Apr; 29 Suppl A():63-70. PubMed ID: 1601759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
    Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
    Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal tolerance of cefpirome (HR 810), a new cephalosporin antibiotic.
    Verho M; Maass L; Malerczyk V; Grötsch H
    Infection; 1987; 15(3):215-9. PubMed ID: 2886437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent.
    Verho M; Malerczyk V; Dagrosa E; Korn A
    Pharmatherapeutica; 1985; 4(6):376-82. PubMed ID: 3866256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves.
    Rajput N; Dumka VK; Sandhu HS
    J Vet Sci; 2007 Mar; 8(1):21-5. PubMed ID: 17322770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefpirome clinical pharmacokinetics.
    Strenkoski LC; Nix DE
    Clin Pharmacokinet; 1993 Oct; 25(4):263-73. PubMed ID: 8261711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
    Van der Werf TS; Fijen JW; Van de Merbel NC; Spanjersberg R; Möller AV; Ligtenberg JJ; Tulleken JE; Zijlstra JG; Stegeman CA
    Intensive Care Med; 1999 Dec; 25(12):1427-31. PubMed ID: 10660852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of cefuroxime after intravenous injection.
    Gower PE; Dash CH
    Eur J Clin Pharmacol; 1977 Nov; 12(3):221-7. PubMed ID: 590309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor.
    Verho M; Korn A; Badian M; Malerczyk V; Waldhäusl W
    Chemotherapy; 1988; 34(3):170-7. PubMed ID: 3166420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.
    Neu HC; Aswapokee P; Fu KP; Ho I; Matthijssen C
    Clin Pharmacol Ther; 1980 May; 27(5):677-85. PubMed ID: 6245831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefpirome during the posttraumatic systemic inflammatory response syndrome.
    Jacolot A; Incagnoli P; Edouard AR; Tod M; Petitjean O; Samii K; Mimoz O
    Intensive Care Med; 1999 May; 25(5):486-91. PubMed ID: 10401943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates.
    Harding SM; Harper PB
    Infection; 1983; 11 Suppl 1():S49-53. PubMed ID: 6339419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
    Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
    Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penetration of cefpirome into the anterior chamber of the human eye after intravenous application.
    Egger SF; Alzner E; Georgopoulos M; Elmenyawi I; Huber-Spitzy V; Georgopoulos A; Grabner G
    J Antimicrob Chemother; 2000 Feb; 45(2):213-6. PubMed ID: 10660503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.